Clinical Trial Update: Regorafenib + Panitumumab for Colorectal Cancers [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating regorafenib in combination with panitumumab for KRAS/NRAS wild-type colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Stivarga (regorafenib)
• Vectibix (panitumumab)

Snippet

Sponsor: University of Utah | Conditions: KRAS and NRAS Wild-type Colorectal Cancer | Phase 1 | Status: TERMINATED